Bruce D. Jackson
Stock Analyst at Benchmark
(2.50)
# 2,317
Out of 5,124 analysts
9
Total ratings
50%
Success rate
19.63%
Average return
Main Sectors:
Stocks Rated by Bruce D. Jackson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EXAS Exact Sciences | Downgrades: Hold | n/a | $101.56 | - | 2 | Nov 24, 2025 | |
| MLSS Milestone Scientific | Maintains: Speculative Buy | $1.25 → $1 | $0.27 | +266.30% | 1 | Nov 20, 2025 | |
| HUMA Humacyte | Maintains: Buy | $14 → $11 | $0.96 | +1,045.24% | 1 | Nov 13, 2025 | |
| BLTE Belite Bio | Maintains: Buy | $80 → $132 | $159.96 | -17.48% | 1 | Oct 31, 2025 | |
| RVPH Reviva Pharmaceuticals Holdings | Maintains: Speculative Buy | $14 → $7 | $0.28 | +2,408.96% | 1 | Sep 15, 2025 | |
| UNCY Unicycive Therapeutics | Maintains: Speculative Buy | $3 → $21 | $5.77 | +263.95% | 1 | Sep 15, 2025 | |
| HBIO Harvard Bioscience | Maintains: Speculative Buy | $3 → $2 | $0.67 | +199.04% | 1 | Sep 10, 2025 | |
| CLNN Clene | Maintains: Buy | $33 → $31 | $5.87 | +428.11% | 1 | Sep 10, 2025 |
Exact Sciences
Nov 24, 2025
Downgrades: Hold
Price Target: n/a
Current: $101.56
Upside: -
Milestone Scientific
Nov 20, 2025
Maintains: Speculative Buy
Price Target: $1.25 → $1
Current: $0.27
Upside: +266.30%
Humacyte
Nov 13, 2025
Maintains: Buy
Price Target: $14 → $11
Current: $0.96
Upside: +1,045.24%
Belite Bio
Oct 31, 2025
Maintains: Buy
Price Target: $80 → $132
Current: $159.96
Upside: -17.48%
Reviva Pharmaceuticals Holdings
Sep 15, 2025
Maintains: Speculative Buy
Price Target: $14 → $7
Current: $0.28
Upside: +2,408.96%
Unicycive Therapeutics
Sep 15, 2025
Maintains: Speculative Buy
Price Target: $3 → $21
Current: $5.77
Upside: +263.95%
Harvard Bioscience
Sep 10, 2025
Maintains: Speculative Buy
Price Target: $3 → $2
Current: $0.67
Upside: +199.04%
Clene
Sep 10, 2025
Maintains: Buy
Price Target: $33 → $31
Current: $5.87
Upside: +428.11%